Aspirin Dose for Cardiovascular Indications
|
|
- Corey Perry
- 6 years ago
- Views:
Transcription
1 PL Detail-Document # This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER September 2012 Aspirin Dose for Cardiovascular Indications Aspirin s cardiovascular benefits stem from its permanent inactivation of platelet COX-1. 8 Inactivation of COX-1 inhibits the production of thromboxane A2, and therefore inhibits thromboxane A2-dependent platelet function and vasoconstriction. 8 Complete or nearly complete inhibition of COX-1 can be achieved with only 75 to 150 mg of aspirin. 8 Daily doses in the range of 50 to 160 mg have been shown to be effective for primary and secondary prevention of cardiovascular events, including prevention of stent restenosis and stroke. 8 In addition to efficacy at the lower doses, there is evidence that gastrointestinal side effects and major bleeding are directly related to aspirin dose. 8 Higher doses can double the risk of GI bleed. 19 These facts support the use of the lowest dose of aspirin that has been found effective in treating/preventing cardiovascular events. 8 This is reflected in the aspirin dosing recommendations in the chart below. The chart provides the aspirin dose for different cardiovascular indications per various guideline-promulgating organizations. (This chart does not include aspirin dosing for orthopedic indications. See our PL Detail-Document, Aspirin for VTE Prophylaxis After Hip or Knee Replacement.) Aspirin dosing recommendations in the guidelines may not reflect the aspirin dosage strengths available on the market. For practical purposes, 81 mg could be used if 75 to 100 mg is recommended, for example. Aspirin should be continued indefinitely for all indications unless otherwise noted. Abbreviations: ACC = American College of Cardiology; ACCF = American College of Cardiology Foundation; ACCP = American College of Chest Physicians; AHA = American Heart Association; ACS = acute coronary syndrome; BMS = bare metal stent; CABG = coronary artery bypass graft; CAD = coronary artery disease; CCS = Canadian Cardiovascular Society; CV = cardiovascular risk; DES = drug-eluting stent; LV = left ventricular; MI = myocardial infarction; NSTEMI = non-st-elevation MI; PCI = percutaneous coronary intervention; SCAI = Society for Cardiovascular Angiography and Interventions; STEMI = ST-elevation MI; UA = unstable angina; USPSTF = United States Preventive Services Task Force. (See footnotes for more details regarding appropriate use.) Indication Aspirin Dose (Adults) Primary prevention of cardiovascular events w USPSTF: 75 mg once daily 1,a ACCP: 75 to 100 mg once daily 5,d CCS: 75 to 162 mg once daily 14,m ADA/AHA/ACCF: 75 to 162 mg once daily 17,u Primary prevention of stroke in women AHA/American Stroke Association: 81 mg once daily or 100 mg every other day 2,b
2 (PL Detail-Document #280901: Page 2 of 8) Indication Aspirin Dose (Adults) Atrial fibrillation (to prevent stroke) ACCP: 75 to 325 mg once daily 4.c CCS: 75 to 325 mg once daily 18,v CAD ACCP: 75 to 100 mg once daily 5 AHA/ACCF: 75 to 162 mg once daily 10,L CCS: 75 to 162 mg once daily 14 Peripheral artery disease AHA/ACCF: 75 to 325 mg once daily 10,L CCS: 75 to 162 mg once daily 14 STEMI AHA/ACCF: chew 162 to 325 mg immediately for acute MI symptoms (unless patient already taking daily aspirin), then 75 to 162 mg once daily 11,e,k (see recommendations for PCI and CABG, as pertinent) ACCP: 75 to 100 mg once daily (maintenance) 5,e,k (see recommendations for PCI and CABG, as pertinent) CSS: 75 to 162 mg once daily (maintenance) 14,k,o (see recommendations for PCI and CABG, as pertinent) UA/NSTEMI AHA/ACCF: chew 162 to 325 mg immediately for ACS symptoms (unless patient already taking daily aspirin), then 75 to 162 mg once daily 7,e,k (see recommendations for PCI and CABG, as pertinent) ACCP: 75 to 100 mg once daily (maintenance) 5,e,k (see recommendations for PCI and CABG, as pertinent) CCS: 75 to 162 mg once daily (maintenance) 14,k,n (see recommendations for PCI and CABG, as pertinent)
3 (PL Detail-Document #280901: Page 3 of 8) Indication CABG Aspirin Dose (Adults) AHA/ACCF: 100 to 325 mg once daily for one year 10,L (see recommendations for CAD, UA/NSTEMI, and STEMI, as pertinent) CCS: 75 to 162 mg once daily (maintenance) 14,r Acute ischemic stroke/tia ACCP: 160 to 325 mg within 48 hours after onset 6 Secondary stroke/tia prevention ACCP: 75 to 100 mg once daily 6 AHA/American Stroke Association: 325 mg within 24 to 48 hours after onset 13 AHA/ACCF: 75 to 325 mg once daily 10,L CCS: 75 to 162 mg once daily 14 PCI, no stent ACCP: 75 to 325 mg once daily for the first month, then 75 to 100 mg once daily (elective, patient with CAD) 5,h,j,k ACCF/AHA/SCAI: continue aspirin indefinitely (see UA/NSTEMI, STEMI, CAD, as pertinent) 9,j,k CCS: 75 to 162 mg once daily 14,k,p PCI, elective, with stent ACCP: 75 to 325 mg once daily for the first month (BMS) or for three to six months (DES), then 75 to 100 mg once daily 5,g,j,k CCS: 75 to 162 mg once daily 14,k,q PCI with stent, post ACS ACCP: 75 to 100 mg once daily 5,e,j,k AHA/ACCF (UA/NSTEMI): 81 mg once daily 9,12.,i,j,k CCS: 75 to 162 mg once daily 14,k,q
4 (PL Detail-Document #280901: Page 4 of 8) Indication Anterior MI with LV thrombus, or at high risk of LV thrombus Aspirin Dose (Adults) ACCP: 75 to 100 mg once daily 5,f,k Mechanical Heart Valve ACCP: 50 to 100 mg once daily 16,t CCS: 75 to 162 mg once daily 14,s a. For men age 45 to 79 years of age and women 55 to 79 years of age if benefit outweighs risk. 1 The CV risk level varies with age and gender and is as follows, and applies only to patients not taking an NSAID who are free of upper GI pain and have no history of ulcer: 3 Men ages 45 to 59 years Women age 55 to 59 Men and women ages 60 to 69 years Men and women ages 70 to 79 years 4% or higher 3% or higher 9% or higher (men) 8% or higher (women) 12% or higher (men) 11% or higher (women) Risk calculators: CHD risk estimation tool (for men): Stroke risk estimation tool (for women): Note: AHA/American Stroke Association guidelines also recommend aspirin (dose not specified) for people with a 10-year cardiovascular event risk of at least 6% to 10%. 2 b. For women whose stroke risk is high enough to justify risks. 2 c. Consider for patients with atrial fibrillation with low stroke risk (CHADS 2 score 0). 2,4 Also option for patients with moderate stroke risk (CHADS 2 score 1) as an alternative to anticoagulation if bleeding risk, patient preference, and patient access to high-quality anticoagulation monitoring makes anticoagulation unfeasible. 2,4 The CHADS 2 score is determined as follows: 1 point each for congestive heart failure, history of hypertension, age over 75 years, or diabetes, and two points for prior stroke or TIA. 2,4 d. Suggested for people 50 years of age and older without symptomatic heart disease. 5 e. Dual antiplatelet therapy is recommended for the first year post-acs. 5,12 f. Without stent placement: add warfarin for the first three months, then switch to dual antiplatelet therapy for up to 12 months. 5 With BMS placement: triple therapy (warfarin plus dual antiplatelet therapy) is suggested for the first month. Warfarin and single antiplatelet therapy is suggested for the second and third months. Thereafter, dual antiplatelet therapy is recommended for up to 12 months. 5
5 (PL Detail-Document #280901: Page 5 of 8) With DES placement: triple therapy (warfarin plus dual antiplatelet therapy) is suggested for the first three to six months. Thereafter, dual antiplatelet therapy is recommended for up to 12 months. 5 g. AHA/ACCF: Dual antiplatelet therapy is recommended for at least the first month after placement of a BMS, and for three to six months after placement of a DES. Continuation of dual antiplatelet therapy for up to 12 months is suggested. 5 AHA/ACCF/SCAI: Use dual antiplatelet therapy for at least 12 months after DES placement if the patient is not at high risk of bleeding. 9 After BMS placement, use dual antiplatelet therapy for at least the first month, and ideally for up to 12 months. If the patient is at increased risk of bleeding risk, then dual antiplatelet therapy should be given for at least two weeks after BMS placement. 9 h. Dual antiplatelet therapy is suggested for the first month. 5 i. With BMS placement: Provide dual antiplatelet therapy for up to 12 months. 12 Other guidelines recommend dual antiplatelet therapy for at least 12 months. 9 Consider earlier discontinuation of second agent if risk of bleeding outweighs anticipated benefits. 12 With DES placement: Provide dual antiplatelet therapy for at least 12 months. 12 Consider earlier discontinuation of second agent if risk of bleeding outweighs anticipated benefits. 12 j. Patients undergoing PCI who have not been taking aspirin should take nonenteric-coated aspirin 325 mg before PCI. Patients already taking aspirin should take 81 to 325 mg before PCI. Patients getting a stent will also receive a loading dose of a P2Y12 inhibitor (e.g., clopidogrel, etc). 9 k. Preference is given to 81 mg daily after PCI as opposed to higher doses. 9,10,12 Use an aspirin maintenance dose of 81 mg with ticagrelor (Brilinta). 12 Canadian ticagrelor labeling recommends an aspirin dose of 75 to 150 mg daily with ticagrelor. 15 L. Use aspirin 75 to 81 mg if the patient is also taking warfarin (e.g., for atrial fibrillation). 10 m. Consider aspirin for patients with: high cardiovascular risk (e.g., multiple risk factors, vascular disease on imaging, elevated CRP) and low bleeding risk; diabetes, other cardiovascular risk factors, and age over 40, with low bleeding risk; or end-stage renal disease with low bleeding risk. 14 n. Use dual antiplatelet therapy for at least one month. Dual antiplatelet therapy can be continued for 12 months in patients without excessive bleeding risk. 14 o. Use dual antiplatelet therapy for at least 14 days, and up to 12 months or longer if bleeding risk is low. 14 p. Post-ACS, use dual antiplatelet therapy for 12 months. Dual therapy may be continued beyond 12 months if thrombosis risk is high and bleeding risk is low. 14 q. BMS: use dual antiplatelet therapy for at least one month (at least two weeks with recent bleed or high bleeding risk), and up to 12 months if bleeding risk is not excessive. Consider dual therapy past one year if high risk of stent thrombosis and low bleeding risk. 14 DES: Use dual antiplatelet therapy for 12 months. Consider dual therapy past one year if high risk of stent thrombosis and low bleeding risk. 14 r. For Non-STEMI managed with CABG, dual antiplatelet therapy is recommended for at least one month, and up to 12 months. For CABG after PCI, use dual antiplatelet therapy for nine to 12 months unless stented vessel adequately bypassed. 14 s. Consider adding aspirin to warfarin, especially in patients with mechanical mitral valve or older caged-ball, tilting disk, or bileaflet mechanical aortic valve. 14 t. Aspirin is suggested as an add-on to warfarin for patients who have a mechanical mitral or aortic valve and low bleeding risk. 16
6 (PL Detail-Document #280901: Page 6 of 8) u. Aspirin is reasonable for patients with diabetes and a 10-year cardiovascular event risk over 10% (e.g., men over 50 years of age and women over 60 years of age with one additional major cardiovascular risk factor [e.g., smoking, hypertension, dyslipidemia, family history of early cardiovascular disease, or albuminuria]) who are not at increased risk of bleeding. 17 v. For patients with a CHADS 2 score (see footnote c) of 0 plus either female sex or vascular disease, or as an oral anticoagulant alternative in patients with a CHADS 2 score of 1, based on risk/benefit. 19 w. Not strongly recommended by most experts. Reserve for high risk patients after a careful benefit/risk assessment. Users of this PL Detail-Document are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and internet links in this article were current as of the date of publication.
7 (PL Detail-Document #280901: Page 7 of 8) Project Leader in preparation of this PL Detail- Document: Melanie Cupp, Pharm.D., BCPS References 1. U.S. Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: recommendation statement. AHRQ Publication No EF-2. March /aspirincvd/aspcvdrs.htm#clinical. (Accessed August 3, 2012). 2. Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42: U.S. Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: clinical summary. AHRQ Publication No EF-3. March /aspirincvd/aspcvdsum.htm. (Accessed August 3, 12). 4. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9 th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(Suppl 2):e531S-75S. 5. Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9 th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(Suppl 2):e637S-68S. 6. Lansberg MG, O Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9 th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(Suppl 2):e601-36S. 7. Wright RS, Anderson JL, Adams CD, et al ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction. J Am Coll Cardiol 2011;57:e Eikelboom JW, Hirsh J, Spencer FA, et al. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9 th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(Suppl 2):e89S-119S. 9. Levine GN, Bates ER, Blankenship JC, et al ACCF/AHA/SCAI guidelines for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011;124:e Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011;124: Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-segment myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Circulation 2004;110:e Jneid H, Anderson JL, Wright S, et al ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non- ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 2012 July 16 [Epub ahead of print]. 13. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association stroke council, clinical cardiology council, cardiovascular radiology and intervention council, and the atherosclerotic peripheral vascular disease and quality of care outcomes in research interdisciplinary working groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007;38: Bell AD, Roussin A, Cartier R, et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines. Can J Cardiol 2011;27(Suppl A):S Product monograph for Brilinta. AstraZeneca Canada Inc. Mississauga, ON L4Y 1M4. May Whitlock RP, Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9 th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(Suppl 2):e576S-e600S. 17. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010;121: Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012;28:
8 (PL Detail-Document #280901: Page 8 of 8) 19. Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005;95: Cite this document as follows: PL Detail-Document, Aspirin Dose for Cardiovascular Indications. Pharmacist s Letter/Prescriber s Letter. September Evidence and Recommendations You Can Trust 3120 West March Lane, P.O. Box 8190, Stockton, CA ~ TEL (209) ~ FAX (209) Subscribers to the Letter can get PL Detail-Documents, like this one, on any topic covered in any issue by going to or
3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationTo provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationAspirin for the Prevention of Cardiovascular Disease
Detail-Document #250601 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER June 2009 ~ Volume 25 ~ Number 250601 Aspirin for the Prevention of Cardiovascular
More informationCardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.
Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. ST Elevation Myocardial Infarction (STEMI)-Acute Coronary Syndrome Guidelines:
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More information2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with American Association for Thoracic Surgery, American
More informationUpdates in Therapeutics: 2013 Pharmacotherapy Preparatory Review and Recertification Course
AMERICAN COLLEGE OF CLINICAL PHARMACY Updates in Therapeutics: 2013 Pharmacotherapy Preparatory Review and Recertification Course POSTTEST ANSWERS SESSION 8 Cardiology I 1. Answer B: NTG intravenously
More informationManagement of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근
Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Case (2011, 5) 74-years old gentleman Exertional chest pain Warfarin with good INR control Ex-smoker, social(?)
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationNorth Wales Cardiac Network Guidelines on oral antiplatelet therapy in cardiovascular disease
Guidelines on oral antiplatelet therapy in cardiovascular disease This guidance should be considered as one part of the wider therapeutic management of patients. The indication for antiplatelet therapy
More informationAntiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology
Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet
More informationGRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017
GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY Nick Collins February 2017 DISCLOSURES Before I commence Acknowledge.. Interventional Cardiologist Perception evolved. Interventional
More informationOptimal lenght of DAPT in different clinical scenarios
Optimal lenght of DAPT in different clinical scenarios After PCI with DES in the light of recent and ongoing studies Dr Grégoire Rangé / CH Chartres / France DAPT duration depend on the evolution of risk
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationFastTest. You ve read the book now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationCoronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide is based on the 2017 KP National Coronary Artery Disease
More informationDIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN
DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN Objectives Gain competence in evaluating chest pain Recognize features of moderate risk unstable angina Review initial management of UA and
More informationThe Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI
The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI Interventional Cardiologist Cardiovascular Institute of the South Director of Cardiovascular Services St. Charles Parish
More informationPerioperative Management. Perioperative Management of Cardiovascular Medications
of Cardiovascular Medications Carmine D Amico, D.O. Overview Learning objectives Beta-blockers Statins Alpha-2 agonists Calcium channel blockers ACE inhibitors and ARB s Anticoagulants Antiplatelet agents
More informationUPDATES FROM THE 2018 ANTIPLATELET GUIDELINES
UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre 21st Annual Contemporary Therapeutic Issues in
More informationSheffield guidelines for the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017)
Sheffield guidelines f the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017) Approved by Sheffield Area Prescribing Committee and Sheffield Teaching Hospitals
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationXarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
More informationDisclosures. Updates in Acute Coronary Syndromes 10/21/17. No Conflicts of Interest. Updates in Acute Coronary Syndromes. Krishan Soni, MD, MBA, FACC
Disclosures Updates in Acute Coronary Syndromes No Conflicts of Interest Krishan Soni, MD, MBA, FACC Assistant Professor of Medicine Division of Cardiology Krishan.soni@ucsf.edu Updates in Acute Coronary
More informationSession 7: Cardiology I and II Answer Explanations
Session 7: Cardiology I and II Answer Explanations Cardiology I 1. Answer A: Intravenous heparin 4000-unit intravenous bolus, followed by a 1000-unit/hour continuous infusion. The NSTE-ACS guidelines recommend
More informationTriple Therapy: A review of the evidence in acute coronary syndrome. Stephanie Kling, PharmD, BCPS Sanford Health
Triple Therapy: A review of the evidence in acute coronary syndrome Stephanie Kling, PharmD, BCPS Sanford Health Objectives 1. Describe how the presented topic impacts patient outcomes. 2. Review evidence
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationANTIPLATELET THERAPY ANTIPLATELET THERAPY ANTIPLATELET THERAPY
ANTIPLATELET THERAPY 2018 UPDATE ANTIPLATELET THERAPY ANTIPLATELET THERAPY About this Pocket Guide This pocket guide is a quick-reference tool that features diagnostic and management recommendations based
More informationHoly Crap! Why is a Cardiologist Speaking at a GI Meeting? Jonathan A. Rapp, MD, FACC, FSCAI Cardiologist, Mercy Heart Institute Cincinnati, OH
Holy Crap! Why is a Cardiologist Speaking at a GI Meeting? Jonathan A. Rapp, MD, FACC, FSCAI Cardiologist, Mercy Heart Institute Cincinnati, OH Goals and Objectives Discuss cardiac considerations for patients
More informationNAVIGATING THROMBOSIS AND BLEEDING AT THE INTERSECTION OF ATRIAL FIBRILLATION AND CORONARY STENTING
NAVIGATING THROMBOSIS AND BLEEDING AT THE INTERSECTION OF ATRIAL FIBRILLATION AND CORONARY STENTING Snehal H. Bhatt, Pharm.D., BCPS-AQ Cardiology, FASHP, AACC Associate Professor of Pharmacy Practice MCPHS
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationMeasurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI)
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for Artery, Atrial Fibrillation, Hypertension
More informationPradaxa (dabigatran)
Pradaxa (dabigatran) Policy Number: 5.01.574 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Pradaxa
More informationHeart disease is the leading cause of death
ACS AND ANTIPLATELET MANAGEMENT: UPDATED GUIDELINES AND CURRENT TRIALS Christopher P. Cannon, MD,* ABSTRACT Acute coronary syndrome (ACS) is an important cause of morbidity and mortality in the US population
More informationHEART OF THE MATTER: cardiac issues in safe endoscopy & sedation
HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation YUVAL KONSTANTINO M.D. CARDIOLOGY DEPARTMENT, ELECTROPHYSIOLOGY UNIT, SOROKA MEDICAL CENTER, BEN-GURION UNIVERSITY OUTLINE 1 2 3 Anticoagulation
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More informationSupplementary Online Content
Supplementary Online Content Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis
More informationISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW
ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP: #204. Ischemic Vascular Disease (IVD):
More informationClinical Practice Guideline for Anticoagulation Management
Clinical Practice Guideline for Anticoagulation Management This guideline is to inform practitioners of the Standard of Care for providing safe and effective anticoagulation management for ambulatory patients.
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy
More information2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Measure #204 (NQF 0068): Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationANTIPLATELET THERAPIES: CURRENT ISSUES. Targeted Literature Review. November 2009
An initiative of NSW clinical pharmacologists and pharmacists funded by the NSW Department of Health ANTIPLATELET THERAPIES: CURRENT ISSUES Targeted Literature Review November 2009 Updated 26 th November
More informationCommon Cardiovascular Risk Calculators
PL Detail-Document #300102 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER January 2014 Common Cardiovascular
More informationMore than 1 million percutaneous coronary intervention
n report n Percutaneous Coronary Intervention: Assessing Coronary Vascular Risk Associated With Bare-Metal and Drug-Eluting Stents Sarah A. Spinler, PharmD, FCCP, BCPS (AQ Cardiology) Abstract Percutaneous
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationTAVI and Valve Replacement Thromboprophylaxis. Warren Prokopiw Pharmacy Resident
TAVI and Valve Replacement Thromboprophylaxis Warren Prokopiw Pharmacy Resident 2011-2012 Case Mr MW 76 yo Admitted 14 May for worsening CHF PMH: Aortic Stenosis, CVD (CABG x4 1980, PCI x3 stent 2008)
More informationDual antiplatelet therapy (DAPT) in the era of Novel Oral Anticoagulants (NOACs) SACIS 2015
Dual antiplatelet therapy (DAPT) in the era of Novel Oral Anticoagulants (NOACs) SACIS 2015 Wesam A Alhejily MD FRCPC FACP FACC FSCAI Assistant Professor of Medicine Chief Of Adult Cardiology Consultant
More informationLong-Term Care Updates
Long-Term Care Updates October/November 2015 By Daniel Kerner, PharmD A stroke occurs when blood flow to the brain is stopped or slowed, resulting in death or damage to brain cells. There are three main
More informationIndications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014
Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014 Indications for cardiac catheterization Before a decision to perform an invasive procedure such
More informationCV Update Guidelines & Debates Royal Pharmaceutical Society, Great Britain Barnet 27/01/09
CV Update Guidelines & Debates Royal Pharmaceutical Society, Great Britain Barnet 27/01/09 Dr Ameet Bakhai, FRCP Cardiologist, Clinical Trials, Health Economics Barnet & Chase Farm NHS Trust Royal Free
More informationCLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA
RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA Dr Lincoff is an interventional cardiologist and the Vice Chairman for Research
More informationCardiovascular Risk in Patients with Diabetes
PL Detail-Document #270516 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER May 2011 Cardiovascular Risk
More informationTransient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction
Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology
More informationAnticoagulants and antiplatelet therapy in the older patient: Choosing wisely
Anticoagulants and antiplatelet therapy in the older patient: Choosing wisely Rajiv Gulati, MD PhD Advances in Cardiac Arrhythmias & Great Innovations in Cardiology Torino, October 2015 2015 MFMER 3477310-1
More informationLessons learned From The National PCI Registry
Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationScope of the Problem: DAPT and Triple Therapy after Stenting
Scope of the Problem: DAPT and Triple Therapy after Stenting Kurt Huber, MD, FESC, FACC 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Session, August 30, 2010,
More informationAlex versus Xience Registry Preliminary report
Interventional Cardiology Network Alex versus Xience Preliminary report Mariusz Gąsior 1,2, Marek Gierlotka 1, Lech Poloński 1,2 1 3rd Department of Cardiology, Medical University of Silesia Centre tor
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More informationClinical Controversies in Perioperative Medicine
Clinical Controversies in Perioperative Medicine Hugo Quinny Cheng, MD Division of Hospital Medicine University of California, San Francisco Predicting & Managing Cardiac Risk A 70-y.o. man with progressive
More informationSupplementary Table S1: Proportion of missing values presents in the original dataset
Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)
More informationBleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM
Bleeding Management Strategies Aiming for the best Outcomes August 27, 2016 Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Learning Objectives Review the use of anti-coagulants in patients
More informationPrimary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College
General Guideline Title Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical
More informationPocket Guide. Antiplatelet Therapy in the Outpatient Setting 2011 Recommendations. Leadership. Knowledge. Community.
Pocket Guide Antiplatelet Therapy in the Outpatient Setting 2011 Recommendations For more information, please visit the Canadian Cardiovascular Society (CCS) Antiplatelet Guidelines at www.ccsguidelineprograms.ca.
More informationDo Not Cite. Draft for Work Group Review.
Defect Free Acute Inpatient Ischemic Stroke Measure Bundle Measure Description Percentage of patients aged 18 years and older with a diagnosis of ischemic stroke OR transient ischemic attack who were admitted
More information6/1/18 LEARNING OBJECTIVES PATIENT POPULATION PRESENTATIONS
PREVENTING HOSPITAL READMISSIONS IN CARDIOVASCULAR PATIENTS Christina Cortez Perry, MSN, FNP-C, CCCC Cardiology Coordinator- Corpus Christi Medical Center 1 2 LEARNING OBJECTIVES Identify the target patient
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More informationJuly ACCP Cardiology PRN Journal Club 7/23/2018
July ACCP Cardiology PRN Journal Club 7/23/2018 Dr. Michael Plazak Dr. Michael Plazak is a PGY2 Cardiology Pharmacy Resident at the University of Maryland School of Pharmacy. He graduated from the University
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationSubclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study
Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study Meagan Sullivan, PharmD PGY2 Cardiology Pharmacy Resident University of Chicago Medicine
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationFølgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved
. Følgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved tilladelse Antithrombotic therapy in Atrial Fibrillation
More informationPL CE LIVE September 2012 Long Guide
This handout accompanies the related articles published in PHARMACIST S LETTER / PRESCRIBER S LETTER September 2012 ~ Volume 28 ~ Number 9 following PL CE LIVE September 2012 Long Guide ASPIRIN You ll
More informationAcute Coronary Syndromes
Overview Acute Coronary Syndromes Rabeea Aboufakher, MD, FACC, FSCAI Section Chief of Cardiology Altru Health System Grand Forks, ND Epidemiology Pathophysiology Clinical features and diagnosis STEMI management
More information2010, Metzler Helfried
Perioperative Strategies in Patients on Dual Antiplatelet Drug Therapy: Noncardiac Surgery H. Metzler Department of Anaesthesiology and Intensive Care Medicine Medical University of Graz, Austria What
More informationANTIPLATELET REGIMENS:
ANTIPLATELET REGIMENS: How Long, How Many? John Carter Hemphill, M.D., F.A.C.C. Chattanooga Heart Institute February 10, 2018 I have no financial disclosures. DISCLOSURES: OBJECTIVES Understand current
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationDAPT in CAD, Acute & Chronic CAD, antiplatelet therapy non-responders
DAPT in CAD, Acute & Chronic CAD, antiplatelet therapy non-responders Annual Ohio ACC Conference October 14, 2017 Ernest L. Mazzaferri Jr, MD, FACC, FSCAI Disclosures No financial disclosures related to
More informationCoronary Artery Disease Clinical Practice Guidelines
Coronary Artery Disease Clinical Practice Guidelines Guidelines are systematically developed statements to assist patients and providers in choosing appropriate healthcare for specific clinical conditions.
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More informationSupplementary Online Content
Supplementary Online Content Amin AP, Spertus JA, Cohen DJ, Chhatriwalla A, Kennedy KF, Vilain K, Salisbury AC, Venkitachalam L, Lai SM, Mauri L, Normand S-LT, Rumsfeld JS, Messenger JC, Yeh RW. Use of
More informationAlberta Colorectal Cancer Screening Program (ACRCSP) Antithrombotic Management
Alberta Colorectal Cancer Screening Program (ACRCSP) Antithrombotic Management Assessment Tools and Suggested Management for the Patient on Antithrombotics Undergoing a Screening-Related Colonoscopy Version
More informationWARFARIN: PERI OPERATIVE MANAGEMENT
WARFARIN: PERI OPERATIVE MANAGEMENT OBJECTIVE: To provide an approach to the perioperative management of warfarin treated patients who require an elective or urgent surgery/procedure. To provide an approach
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationPathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL
Pathology of percutaneous interventions (PCI) in coronary arteries Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL Percutaneous Coronary Intervention (PCI) Definition: transcatheter opening of
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationDr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου
Dr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου Θεσσαλονίκη, 9/2/2018 Disclosures: None Primary efficacy outcome* (%/year) Antiplatelet Therapy
More information